A175250 Stock Overview
Icure Pharmaceutical Incorporation, a biopharmaceutical company, researches, develops, and sells pharmaceutical and cosmetic products in South Korea.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Icure Pharmaceutical Incorporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩2,100.00 |
52 Week High | ₩4,225.00 |
52 Week Low | ₩1,775.00 |
Beta | 1.12 |
1 Month Change | -8.50% |
3 Month Change | 0.48% |
1 Year Change | -46.90% |
3 Year Change | -88.36% |
5 Year Change | -85.80% |
Change since IPO | -90.02% |
Recent News & Updates
Shareholder Returns
A175250 | KR Personal Products | KR Market | |
---|---|---|---|
7D | 0% | 5.5% | 2.4% |
1Y | -46.9% | -13.0% | 12.2% |
Return vs Industry: A175250 underperformed the KR Personal Products industry which returned -12.4% over the past year.
Return vs Market: A175250 underperformed the KR Market which returned 13% over the past year.
Price Volatility
A175250 volatility | |
---|---|
A175250 Average Weekly Movement | 13.2% |
Personal Products Industry Average Movement | 5.1% |
Market Average Movement | 5.2% |
10% most volatile stocks in KR Market | 11.9% |
10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A175250's share price has been volatile over the past 3 months.
Volatility Over Time: A175250's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 199 | n/a | https://www.icure.co.kr |
Icure Pharmaceutical Incorporation, a biopharmaceutical company, researches, develops, and sells pharmaceutical and cosmetic products in South Korea. The company offers functional, nature-derived, derma, and customized cosmetics products. It also offers eye gel, hydro nude gel, lip gel mask, and functional patch products; and sheet, mud, foil, and melting masks.
Icure Pharmaceutical Incorporation Fundamentals Summary
A175250 fundamental statistics | |
---|---|
Market cap | ₩78.48b |
Earnings (TTM) | -₩31.42b |
Revenue (TTM) | ₩56.81b |
1.4x
P/S Ratio-2.5x
P/E RatioIs A175250 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A175250 income statement (TTM) | |
---|---|
Revenue | ₩56.81b |
Cost of Revenue | ₩55.51b |
Gross Profit | ₩1.30b |
Other Expenses | ₩32.72b |
Earnings | -₩31.42b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -840.79 |
Gross Margin | 2.28% |
Net Profit Margin | -55.31% |
Debt/Equity Ratio | 128.0% |
How did A175250 perform over the long term?
See historical performance and comparison